Full history for every metric is available with a Kvantra account
Key financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CHF m | 402 | 503 | 532 | 577 | 605 | 695 | 709 | 942 |
| Operating profit | CHF m | 150 | 137 | ||||||
| Net profit | CHF m | 78 | 115 | 101 | 112 | 120 | 149 | 149 | 181 |
| EPS reported | CHF | 1.98 | 1.99 | ||||||
| Operating cashflow per share | CHF | 3.62 | 3.87 | ||||||
| Capex per share | CHF | 4.26 | 4.50 | ||||||
| FCF per share | CHF | -0.64 | -0.63 | ||||||
| Free cash flow | CHF m | -48 | -47 | ||||||
| Net debt | CHF m | 26 | 157 | ||||||
| Book value equity | CHF m | 1,458 | 1,444 | ||||||
| Book value per share | CHF | 19.45 | 19.27 | ||||||
| Number of shares | m | 74.96 | 74.94 | ||||||
| DPS (TTM paid) | CHF | 0.90 | 0.90 |
Financial summary
Financials in CHF| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 30.25 | - | ||||||
| P/B LTM | x | 3.08 | 4.12 | ||||||
| P/S LTM | x | 6.46 | 8.39 | ||||||
| P/FCF LTM | x | -93.15 | -125.36 | ||||||
| EV/EBITDA LTM | x | 23.79 | 32.18 | ||||||
| EV/Sales LTM | x | 6.50 | 8.61 | ||||||
| Earnings Yield LTM | % | 3.31% | 2.51% | ||||||
| FCF Yield | % | -1.07% | -0.80% | ||||||
| Quality | |||||||||
| ROE | % | 10.20% | 10.27% | ||||||
| ROIC | % | 8.12% | 6.43% | ||||||
| Operating margin | % | 21.62% | 19.41% | ||||||
| Gross margin | % | 28.74% | 27.00% | ||||||
| FCF/Sales | % | -6.93% | -6.69% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +23.75% | +11.17% | ||||||
| Sales Growth YoY | % | +14.84% | +4.51% | ||||||
| Net Income Growth YoY | % | +23.74% | +11.01% | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | +12.96% | -15.91% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.68% | 1.13% | ||||||
| Dividend Growth | % | +5.88% | +5.88% | ||||||
| Payout Ratio | % | 20.70% | 20.65% | ||||||
| FCF/Debt | x | -0.84 | -0.23 | ||||||
| Net Debt/EBITDA | x | 0.14 | 0.83 | ||||||
| EBIT/Net interest | x | 310.51 | 110.97 | ||||||
| Net debt/market cap | % | 0.59% | 2.63% | ||||||
| Net debt/Equity | x | 0.02 | 0.11 | ||||||
| Gross debt/equity | x | 0.04 | 0.14 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Based on consensus from external analysts. Not Kvantra's opinion.
Bachem Holding AG serves pharmaceutical and biotechnology companies globally, providing products crucial for research, clinical development, and commercial use. The company's primary focus is on the design, manufacturing, and regulatory support for peptide active pharmaceutical ingredients (APIs), specifically targeting novel peptide and oligonucleotide chemical entities (NCEs). Additionally, Bachem offers commercially available NCEs and generic compounds. Its comprehensive service portfolio includes project management, quality assurance and regulatory guidance, analytical testing, production adhering to Good Manufacturing Practices (GMP), manufacturing for research purposes, and expertise in supply chain and vertical integration. Established in 1971, Bachem Holding AG is headquartered in Bubendorf, Switzerland, and functions as a subsidiary of Ingro Finanz AG.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free